No products in the cart.
-
Sale
A-B1 100 mgThiamine is specifically used in the treatment of the various manifestations of thiamine deficiency such as Beriberi and Wernick's encephalopathy, neuritis associated with pregnancy and pellagra. Supplementary Thiamine may be indicated prophylactically in conditions where there is low dietary intake ... Read moreThiamine is specifically used in the treatment of the various manifestations of thiamine deficiency such as Beriberi and Wernick's encephalopathy, neuritis associated with pregnancy and pellagra. Supplementary Thiamine may be indicated prophylactically in conditions where there is low dietary intake or impaired gastro intestinal absorption of thiamine (e.g. alcohol) or where requirements are increased (pregnancy, carbohydrate rich diet).Theropeutic ClassVitamin-B preparationsPharmacologyThiamine, in the form of thiamine pyrophosphate, is the coenzyme for decarboxylation of ?-ketoglutaric acid. Thiamine deficiency affects the peripheral nervous system, the gastrointestinal tract, and the cardiovascular system. This vitamin is necessary for the optimal growth of infants and children. Thiamine is not stored in the body, and is regularly lost from tissues during short periods of deficiency. In order to maintain normal health, an adequate amount of thiamine is required every day. Deficiency of thiamine leads to fatigue, anorexia, gastrointestinal disturbance, tachycardia, irritability and neurological symptoms. Beriberi, a disease due to vitamin B1 deficiency, is common in alcoholics, in pregnant women receiving an inadequate diet, and in people with malabsorption syndrome, prolonged diarrhoea and hepatic disease.Thiamine is well absorbed from the gastrointestinal tract and widely distributed throughout the body. Thiamine is rapidly absorbed from the upper small intestine. Thiamine is not stored in the body to any appreciable extent. Excess ingested thiamine appears in urine as intact thiamine or as pyrimidine, which arises from degradation of the thiamine molecule. The plasma half life of thiamine is 24 hours.Dosage & Administration of A-B1 100 mgProphylaxis: 3 to 10 mg daily.Mild chronic deficiency: 10 to 25 mg daily.Severe deficiency: 200 to 300 mg daily.Dosage of A-B1 100 mgProphylaxis: 3 to 10 mg daily.Mild chronic deficiency: 10 to 25 mg daily.Severe deficiency: 200 to 300 mg daily.Interaction of A-B1 100 mgNo hazardous drug interactions have been reported. Vitamin B1 acts synergistically with other vitamins of the B-complex group and its potential for causing adverse effects is considerably reduced.ContraindicationsThere is no absolute contraindication but the risk of anaphylaxis is increased by repeated parenteral administration.?Mild allergic phenomena, such as sneezing or mild asthma are warning signs that further may give rise to anaphylactic shock. To avoid this possibility it is advisable to start a second course of injection with a dose considerably lower than that previously used. Because of the above, vitamin B1 injection should not be given intravenously except in the case of comatose patients. Once thiamine deficiency is corrected there is no need for parenteral administration or for the administration of amounts in excess of daily requirement.Side Effects of A-B1 100 mgVitamin B1 does not have adverse effects when given orally, but in a few fatal cases anaphylactic reactions have occurred after intravenous administration of large doses (400 mg) in sensitive patients, especially children, and in one case following an intramuscular dose of 125 mg. The risk of such reactions increases with repeated administration of the drug by parenteral route. Transient mild soreness may occur at the site of intramuscular administrationPregnancy & LactationThe drug may be given safely to neonates, children, pregnant and lactating women and elderly patients.Storage ConditionsThiamine injection should be protected from light and moisture.Drug ClassesVitamin-B preparationsMode Of ActionThiamine, in the form of thiamine pyrophosphate, is the coenzyme for decarboxylation of ?-ketoglutaric acid. Thiamine deficiency affects the peripheral nervous system, the gastrointestinal tract, and the cardiovascular system. This vitamin is necessary for the optimal growth of infants and children. Thiamine is not stored in the body, and is regularly lost from tissues during short periods of deficiency. In order to maintain normal health, an adequate amount of thiamine is required every day. Deficiency of thiamine leads to fatigue, anorexia, gastrointestinal disturbance, tachycardia, irritability and neurological symptoms. Beriberi, a disease due to vitamin B1 deficiency, is common in alcoholics, in pregnant women receiving an inadequate diet, and in people with malabsorption syndrome, prolonged diarrhoea and hepatic disease.Thiamine is well absorbed from the gastrointestinal tract and widely distributed throughout the body. Thiamine is rapidly absorbed from the upper small intestine. Thiamine is not stored in the body to any appreciable extent. Excess ingested thiamine appears in urine as intact thiamine or as pyrimidine, which arises from degradation of the thiamine molecule. The plasma half life of thiamine is 24 hours.PregnancyThe drug may be given safely to neonates, children, pregnant and lactating women and elderly patients.A-B1100 mg
Original price was: ₦473.00.₦425.70Current price is: ₦425.70. -
SaleA-Calm 50 mgA-Calm 50 mg is indicated in- Treatment of increased tone of skeletal muscles due to organic neurological disorders (injury of the pyramidal tract, multiple sclerosis, myelopathy, encephalomyelitis). Treatment of muscular spasm, muscular contracture, rigidity, spinal automatism. ... Read moreA-Calm 50 mg is indicated in- Treatment of increased tone of skeletal muscles due to organic neurological disorders (injury of the pyramidal tract, multiple sclerosis, myelopathy, encephalomyelitis). Treatment of muscular spasm, muscular contracture, rigidity, spinal automatism. In the treatment of vascular diseases (Obliterative arteriosclerosis, diabetic angiopathy, obliterative thromboangitis, Raynaud's disease, diffuse scleroderma). In individual cases, post-thrombotic venous and lymphatic circulation disorders and crural ulcer. Theropeutic ClassCentral Depolarizing muscle relaxants, Centrally acting Skeletal Muscle RelaxantsPharmacologyTolperisone is a centrally acting muscle relaxant that acts at the reticular formation in the brain stem by blocking voltage-gated sodium and calcium channelsDosage & Administration of A-Calm 50 mgAdult: 150-450 mg daily, administered in 2 or 3 divided doses. The maximum dosage is 450 mg/day.Children: 3 months to 6 years: 1-2 mg/kg/day in 3 divided doses. 6 years to 14 years: 2-4 mg/kg/day in 3 divided doses Dosage of A-Calm 50 mgThe recommended dose is as follows: Adult: 50-150 mg three times daily according to the individual requirement and tolerance of the patient. Children (from 3 months to 6 years): 5 mg/kg/day in three divided doses. Children (from 6 to 14 years): 2-4 mg/kg/day in three divided doses. or, as directed by the registered physician. Interaction of A-Calm 50 mgConcomitant use of methocarbamol with A-Calm 50 mg has been reported to cause disturbance of visual accommodation.ContraindicationsIt is contraindicated in patients with a history of hypersensitivity to any component of the product, myasthenia gravis and nursing mother.Side Effects of A-Calm 50 mgPossible side-effects include sometimes muscular weakness, headache, nausea, vomiting and rarely hypersensitivity reactions (itching, redness of the skin, skin rash) may occur.Pregnancy & LactationA-Calm 50 mg should be used in pregnancy according to physician's advice. Tolperisone hydrochloride should not be used during breast-feeding.Precautions & WarningsIn case of children, the prescribed dose and duration of treatment should closely be observed.Overdose Effects of A-Calm 50 mgExcitability has been noted after ingestion of high doses by children. In suicide studies of three isolated cases, it is believed that ingestion of tolperisone was the cause of death.Storage ConditionsKeep below 30?C temperature, away from light & moisture. Keep out of the reach of children.Drug ClassesCentral Depolarizing muscle relaxants, Centrally acting Skeletal Muscle RelaxantsMode Of ActionA-Calm 50 mg is a centrally acting muscle relaxant, which acts on the central nervous system and used mainly for the treatment of elevated muscle tone and tension as well as for certain circulation problems in the extremities.PregnancyA-Calm 50 mg should be used in pregnancy according to the physician's advice. It should not be used during breast feeding.
A-Calm50 mg
Original price was: ₦440.00.₦396.00Current price is: ₦396.00. -
SaleA-Flox 500 mgA-Flox 500 mg is indicated for the treatment of infections caused by Gram-positive organisms, including those resulting from penicillinase-producing staphylococci. These indications encompass a wide range of conditions: Skin and Soft Tissue Infections: This includes boils, abscesses, carbuncles, and various infected skin conditions such as ulcers, eczema, acne, furunculosis, cellulitis, as well as infected wounds and burns. Respiratory Tract Infections: Flucloxacillin is effective against pneumonia, lung abscesses, empyema, sinusitis, pharyngitis, tonsillitis, and quinsy. Other Infections: It is also utilized for treating osteomyelitis, enteritis, endocarditis, urinary tract infections, meningitis, and septicaemia caused by organisms sensitive to A-Flox 500 mg. Prophylactic Use: In addition, it serves as a prophylactic agent during major surgical procedures, particularly in cardiothoracic and orthopedic surgery when deemed appropriate.Theropeutic ClassPenicillinase-resistant penicillinsPharmacologyFlucloxacillin is effective against Gram-positive organisms, including those that produce penicillinase. It exhibits limited activity against Gram-negative bacilli. The mode of action of Flucloxacillin involves the inhibition of bacterial cell wall formation. As an isoxazolyl penicillin, Flucloxacillin combines key properties such as resistance to penicillinase hydrolysis, stability in gastric acid conditions, and activity against Gram-positive bacteria. This bactericidal antibiotic is particularly valuable in combating penicillinase-producing staphylococci. Flucloxacillin works by disrupting peptidoglycan synthesis, a vital component of the bacterial cell wall that provides mechanical stability. In the final step of peptidoglycan synthesis, Flucloxacillin inhibits the transpeptidase enzyme responsible for cross-linking, specifically preventing the linkage of the terminal glycine residue to the fourth residue of the pentapeptide (D-alanine). The bacterial cell wall weakens, leading to swelling and eventual rupture. Flucloxacillin's resistance to bacterial penicillinase likely arises from steric hindrance induced by its acyl side chain, preventing the opening of the ?-lactam ring.Dosage of A-Flox 500 mgOral Administration: Adults: Take 250 mg four times a day. The dosage may be doubled in severe infections. For osteomyelitis and endocarditis, a daily dose of up to 8 grams is administered in 6-8 hourly divided doses. Children (2-10 years): Use half of the adult dose. Children (Under 2 years): Use a quarter of the adult dose. Parenteral Administration: Adults or Elderly: Intramuscular Injection: Take 250 mg four times daily. Intravenous Injection: Administer 250 mg to 1 gram four times daily, either through slow injection over 3 to 4 minutes or by intravenous infusion. In severe infections, all systemic doses can be doubled, with doses of up to 8 grams daily suggested for endocarditis or osteomyelitis. Children: For children aged 2-10 years, use half of the adult dose. For children under 2 years, use a quarter of the adult dose. Administration of A-Flox 500 mgOral doses should be administered 1 hour before meal.Interaction of A-Flox 500 mgFor severe renal failure (creatinine clearance <10 ml/min), it is advisable to contemplate a dose reduction or an extension of the dosing interval.ContraindicationsA-Flox 500 mg is contraindicated in penicillin hypersensitive patients.Side Effects of A-Flox 500 mgCommon side effects affecting the gastrointestinal tract include nausea, vomiting, diarrhea, dyspepsia, and other minor gastrointestinal disturbances. Reports have indicated occurrences of rashes, urticaria, purpura, fever, interstitial nephritis, hepatitis, and cholestatic jaundice.Precautions & WarningsExercise caution when administering A-Flox 500 mg to patients exhibiting signs of liver dysfunction.?Additionally, be cautious when treating patients with an allergic predisposition.Storage ConditionsKeep in a dry place away from light and heat. Keep out of the reach of children.Use In Special PopulationsFor severe renal failure (creatinine clearance <10 ml/min), it is advisable to contemplate a dose reduction or an extension of the dosing interval.ReconstitutionA-Flox 500 mg has been employed through alternative administration routes in combination with systemic therapy. It has been dosed at 250 mg to 500 mg per day via intra-articular injection, potentially dissolved in a 0.5% solution of lignocaine hydrochloride, as well as through intrapleural injection at a daily dosage of 250 mg. Using the powder for injection, 125 mg to 250 mg has been dissolved in 3 ml of sterile water and administered via nebulizer four times daily.Drug ClassesPenicillinase-resistant penicillinsMode Of ActionFlucloxacillin exhibits activity against Gram-positive organisms, including strains that produce penicillinase. Its efficacy against Gram-negative bacilli is limited. The mechanism of action involves the inhibition of bacterial cell wall formation. Flucloxacillin, classified as an isoxazolyl penicillin, possesses unique qualities such as resistance to hydrolysis by penicillinase, stability in gastric acid conditions, and effectiveness against Gram-positive bacteria. This bactericidal antibiotic is particularly valuable in combatting penicillinase-producing staphylococci. Flucloxacillin disrupts bacterial cell wall synthesis, specifically interfering with peptidoglycan production. Peptidoglycan is a complex structure that provides mechanical stability to the cell wall. The final step in peptidoglycan synthesis, which involves cross-linking with the terminal glycine residue of the pentaglycin bridge connecting to the fourth residue of the pentapeptide (D-alanine), is hindered by Flucloxacillin. Consequently, the bacterial cell wall weakens, leading to cell swelling and eventual rupture. Flucloxacillin's resistance to bacterial penicillinase is likely attributed to steric hindrance caused by its acyl side chain, preventing the opening of the ?-lactam ring.PregnancyThe US FDA Pregnancy Category for A-Flox 500 mg is B. There are no adequate and well-controlled studies conducted in pregnant women. Since animal reproduction studies may not always accurately predict human responses, it is advisable to use this medication during pregnancy only when it is clearly necessary. A-Flox 500 mg has been demonstrated to be excreted in human milk, so caution should be exercised when administering it to a lactating mother.Pediatric UsesIn severe renal failure (creatinine clearance <10 ml/min), a reduction in dose or an extension of dose interval should be considered.
A-Flox500 mg
Original price was: ₦770.00.₦693.00Current price is: ₦693.00. -
SaleA-Meb 135 mgMebeverine is indicated for the: Symptomatic treatment of irritable bowel syndrome (IBS) Chronic irritable colon Spastic constipation Mucous colitis Colicky abdominal pain Persistent non-specific diarrhoea Theropeutic ClassAnticholinergicsPharmacologyMebeverine is a musculotropic antispasmodic agent used to relieve cramps or spasms of the stomach and intestine (gut). It is particularly useful in treating Irritable Bowel Syndrome (IBS) and similar conditions. It works by relaxing the muscles and helping to restore the normal movement of the gut.Dosage & Administration of A-Meb 135 mgFor adults, elderly and children over 10 years: Mebeverine Tablet: 1 tablet 03 times daily. Mebeverine 200 SR Capsule: 1 capsule 02 times daily. This is most effective when taken 20 minutes before meals. After several weeks when the desired effect has been obtained, the dosage may be gradually reduced.Missed dose: If a dose of this medicine is missed, that should be taken as soon as possible. However, if it is almost time for the next dose, then skip the missed dose and the regular dosing schedule should be maintained. Dose should not be doubled at the same time to compensate the missed dose.Dosage of A-Meb 135 mgFor adults, elderly and children over 10 years: A-Meb 135 mg 135 mg tablet: 1 tablet 03 times daily. A-Meb 135 mg 200 mg capsule: 1 capsule 02 times daily. This is most effective when taken 20 minutes before meals. After several weeks when the desired effect has been obtained, the dosage may be gradually reduced.Missed dose: If a dose of this medicine is missed, that should be taken as soon as possible. However, if it is almost time for the next dose, then skip the missed dose and the regular dosing schedule should be maintained. Dose should not be doubled at the same time to compensate the missed dose.Use in children: Mebeverine is not recommended for children under 10 years.Interaction of A-Meb 135 mgNot known.ContraindicationsHypersensitivity to the drug or any other ingredients.Side Effects of A-Meb 135 mgGenerally Mebeverine is well tolerated. However, few side-effects like skin rash, urticaria and angioedema may appearPregnancy & LactationNo teratogenicity has been shown in animal experiments. However, the usual precautions concerning the administration of any drug during pregnancy should be exercised. Mebeverine does not excrete in the breast milk after administering the therapeutic dose.Precautions & WarningsCaution should be exercised in porphyria or allergic reaction to this or any other medicine of this group.Overdose Effects of A-Meb 135 mgOn theoretical grounds it may be predicted that CNS excitability will occur in case of overdosage. No specific antidote is known: gastric lavage and symptomatic treatment is recommendedStorage ConditionsDo not store above 30?C. Keep away from light and out of the reach of children.Use In Special PopulationsUse in children: Mebeverine is not recommended in children under 10 years.Drug ClassesAnticholinergicsPregnancyNo teratogenicity has been shown in animal experiments. However, the usual precautions concerning the administration of any drug during pregnancy should be exercised. Mebeverine does not excrete in the breast milk after administering at therapeutic dose.
A-Meb135 mg
Original price was: ₦330.55.₦297.55Current price is: ₦297.55. -
SaleA-Mycin 3%For topical treatment of acne, pimples & bacterial skin infections susceptible to A-Mycin 3%.Theropeutic ClassTopical antibiotics for AcnePharmacologyA-Mycin 3% is a bacteriostatic macrolide antibiotic. But may be bactericidal in high concentrations. Although the mechanism by which A-Mycin 3% acts in reducing the inflammatory lesions of acne vulgaris is unknown, it is presumably due to the antibiotic action of the drug.Dosage & Administration of A-Mycin 3%Apply in morning and evening to the affected areas. Before applying thoroughly wash with warm water and soap, rinse and pat dry all areas to be treated. Apply with fingertips or applicator. Wash hands after use. Spread the medication lightly rather than rubbing it in. Acne lesions on the face, neck, shoulders, chest and back may be treated in this manner. Additional containers may be used, if needed. Each container should be used once and discarded.Interaction of A-Mycin 3%Clindamycin interacts with A-Mycin 3%.ContraindicationsHypersensitivity to A-Mycin 3% or to any of the other ingredients of the lotion.Side Effects of A-Mycin 3%Erythema, desquamation, burning sensation, eye irritation, tenderness, dryness, oily skin etc.Pregnancy & LactationSafety for use during pregnancy has not been established. Use only when the potential benefits outweigh potential hazards to the fetus. A-Mycin 3% is excreted in breast milk. Exercise caution when administering to a nursing mother.Precautions & WarningsFor external use only. Keep away from eyes, nose, mouth and other mucous membrane. Use of antibiotics (especially prolonged or repeated therapy) may result in bacterial or fungal overgrowth of non-susceptible organisms. Such overgrowth may lead to a secondary infection. Take appropriate measures if superinfections occur.Storage ConditionsKeep below 25?C temperature, away from light & moisture. Keep out of the reach of children.Use In Special PopulationsSafety and effectiveness in children less than 12 years have not been established.
A-Mycin3%
Original price was: ₦6,600.00.₦6,006.00Current price is: ₦6,006.00. -
SaleAbasaglar Cartridge 100 IU/mlAbasaglar Cartridge 100 IU/ml is indicated to improve glycemic control in adults and children with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.Theropeutic ClassLong Acting InsulinPharmacologyAbasaglar Cartridge 100 IU/ml is a sterile solution of insulin glargine for use as a subcutaneous injection. Insulin glargine is a recombinant human insulin analogue that is a long-acting (up to 24-hour duration of action), parenteral blood glucose lowering agent. Abasaglar Cartridge 100 IU/ml is produced by recombinant DNA technology. Primary function of insulin glargine is regulation of glucose metabolism. Insulin and its analogues lower blood glucose by stimulation peripheral glucose uptake, primarily by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis and enhances protein synthesis.Dosage of Abasaglar Cartridge 100 IU/mlAbasaglar Cartridge 100 IU/ml exhibits a relatively constant glucose-lowering profile over 24 hours that permits once-daily dosing. Potency of insulin glargine is approximately the same as human insulin.Insulin Glargine is recommended for once daily subcutaneous administration & may be administered at any time during the day. However, once started should be administered at the same time every day. The dose of Insulin Glargine must be individualized based on clinical response. Blood glucose monitoring is essential in all patients with diabetes. In patients with type 1 diabetes, Insulin Glargine must be used in regimens with short-acting insulin. Insulin Glargine is not recommended for intravenous administration. Intravenous administration of the usual subcutaneous dose could result in severe hypoglycemia. Initiation of Insulin Glargine therapy: The recommended starting dose of Insulin Glargine in patients with type 1 diabetes should be approximately one-third of the total daily insulin requirements. Short-acting, premeal insulin should be used to satisfy the remainder of the daily insulin requirements. The recommended starting dose of Insulin Glargine in patients with type 2 diabetes who are not currently treated with insulin is 10 units (or 0.2 Units/kg) once daily, which should subsequently be adjusted to the patient's needs. Converting to Insulin Glargine from other insulin therapies: If changing from a treatment regimen with an intermediate-or long-acting insulin to a regimen with Insulin Glargine , the amount and timing of shorter-acting insulins and doses of any oral anti-diabetic drugs may need to be adjusted. If transferring patients from once-daily NPH insulin to once-daily Insulin Glargine , the recommended initial Insulin Glargine dose is the same as the dose of NPH that is being discontinued. If transferring patients from twice-daily NPH insulin to once-daily Insulin Glargine , the recommended initial Insulin Glargine dose is 80% of the total NPH dose that is being discontinued.Administration of Abasaglar Cartridge 100 IU/mlAbasaglar Cartridge 100 IU/ml should be injected subcutaneously once daily at any time of day, but at the same time everyday. Cartridge: Insert the Insulin Glargine cartridge into the pen correctly and equip the needle. Gently turn the pen upside down for 8-10 times until the insulin in the cartridge becomes uniformly mixed. Adjust the dosage button to get correct dose. After removal of the needle cap and discharge air bubbles in the cartridge, it is ready to be injected. In order to avoid cross contamination, do not let the needle touch anything during the process of preparation. Vial: Firstly, clean your hands. Shake or rotate the vial gently to mix the solution uniformly and check if the insulin has the normal appearance. If using a new Insulin Glargine bottle then flip off the plastic protective cap and wipe the rubber stopper with an alcohol swab. Draw air into your syringe equal to the amount of Insulin Glargine needed. Puncture the needle into the vial and inject the air. Turn the bottle and syringe upside down. Withdraw correct dose of Insulin Glargine into the syringe. Before pulling out the needle, check if there are any bubbles remain in the syringe. If so, put the syringe upright and tap the syringe to discharge the air bubbles. Injection Site: Choose the area where skin is less tight, such as the upper arm, thigh, buttock and abdomen, etc. To avoid tissue damage, choose a site for each injection that is at least 1 cm from the previous injection site. Injection Method: Cleanse the skin with alcohol where the injection is to be made. Put the needle in such a position as to form 45? angle with the skin. Puncture the needle into skin and inject insulin. Then pull the needle out and apply gentle pressure over the injected site for several seconds. Do not rub the injection site.Interaction of Abasaglar Cartridge 100 IU/mlA number of drugs affect glucose metabolism and may require dose adjustment. The following substances may reduce the Insulin as well as Insulin glargine requirements: Oral anti-diabetic products, angiotensin converting enzyme (ACE) inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, propoxyphene, pentoxifylline, salicylates and sulfonamide antibiotics. The following substances may increase the Insulin as well as Insulin glargine requirements: Thiazides, glucocorticoids, thyroid hormones, beta-sympathomimetics, growth hormone and danazol. Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.ContraindicationsAbasaglar Cartridge 100 IU/ml is contraindicated in patients with hypersensitivity to insulin glargine or any of its excipients.Side Effects of Abasaglar Cartridge 100 IU/mlSide effects of Insulin glargine are hypoglycemia, allergic reactions, injection site reaction, lipodystrophy, pruritus, and rash.Pregnancy & LactationPregnancy category C. Insulin glargine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Lactation: It is unknown whether insulin glargine is excreted in human milk. Because many drugs, including human insulin, are excreted in human milk, caution should be exercised when Insulin glargine is administered to a nursing woman. Lactating women may require adjustments in insulin dose & diet.Precautions & WarningsDose adjustment and monitoring: Blood glucose should be monitored in all patients treated with insulin. Insulin regimens should be modified cautiously and only under medical supervision. Administration: Insulin glargine must not be diluted or mixed with any other insulin or solution. It should not be administered subcutaneously via an insulin pump or intravenously because severe hypoglycemia can occur. Renal or hepatic impairment: Reduction in the Insulin glarginedose may require in these cases.Overdose Effects of Abasaglar Cartridge 100 IU/mlAbasaglar Cartridge 100 IU/ml overdose may result in hypoglycemia. Mild episodes of hypoglycemia can usually be treated with oral carbohydrates. Severe hypoglycemia may be treated with parenteral glucose or injections of glucagon. Adjustments in drug dosage, meal patterns, or exercise may be needed.Storage ConditionsStore at 2? C to 8? C in a refrigerator. Do not freeze. In case of insulin for recent use need not to be refrigerated, try to keep it in a cool place and keep away from heat and light. The insulin in use can be kept under the room temperature for a month.Use In Special PopulationsUse in Renal/ Hepatic impairment: Reduction in the insulin glargine doses may be required in these cases.
Abasaglar Cartridge100 IU/ml
Original price was: ₦49,225.00.₦47,256.00Current price is: ₦47,256.00. -
SaleAbasaglar Kwikpen 100 IU/mlAbasaglar Kwikpen 100 IU/ml is indicated to improve glycemic control in adults and children with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.Theropeutic ClassLong Acting InsulinPharmacologyAbasaglar Kwikpen 100 IU/ml is a sterile solution of insulin glargine for use as a subcutaneous injection. Insulin glargine is a recombinant human insulin analogue that is a long-acting (up to 24-hour duration of action), parenteral blood glucose lowering agent. Abasaglar Kwikpen 100 IU/ml is produced by recombinant DNA technology. Primary function of insulin glargine is regulation of glucose metabolism. Insulin and its analogues lower blood glucose by stimulation peripheral glucose uptake, primarily by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis and enhances protein synthesis.Dosage of Abasaglar Kwikpen 100 IU/mlAbasaglar Kwikpen 100 IU/ml exhibits a relatively constant glucose-lowering profile over 24 hours that permits once-daily dosing. Potency of insulin glargine is approximately the same as human insulin.Insulin Glargine is recommended for once daily subcutaneous administration & may be administered at any time during the day. However, once started should be administered at the same time every day. The dose of Insulin Glargine must be individualized based on clinical response. Blood glucose monitoring is essential in all patients with diabetes. In patients with type 1 diabetes, Insulin Glargine must be used in regimens with short-acting insulin. Insulin Glargine is not recommended for intravenous administration. Intravenous administration of the usual subcutaneous dose could result in severe hypoglycemia. Initiation of Insulin Glargine therapy: The recommended starting dose of Insulin Glargine in patients with type 1 diabetes should be approximately one-third of the total daily insulin requirements. Short-acting, premeal insulin should be used to satisfy the remainder of the daily insulin requirements. The recommended starting dose of Insulin Glargine in patients with type 2 diabetes who are not currently treated with insulin is 10 units (or 0.2 Units/kg) once daily, which should subsequently be adjusted to the patient's needs. Converting to Insulin Glargine from other insulin therapies: If changing from a treatment regimen with an intermediate-or long-acting insulin to a regimen with Insulin Glargine , the amount and timing of shorter-acting insulins and doses of any oral anti-diabetic drugs may need to be adjusted. If transferring patients from once-daily NPH insulin to once-daily Insulin Glargine , the recommended initial Insulin Glargine dose is the same as the dose of NPH that is being discontinued. If transferring patients from twice-daily NPH insulin to once-daily Insulin Glargine , the recommended initial Insulin Glargine dose is 80% of the total NPH dose that is being discontinued.Administration of Abasaglar Kwikpen 100 IU/mlAbasaglar Kwikpen 100 IU/ml should be injected subcutaneously once daily at any time of day, but at the same time everyday. Cartridge: Insert the Insulin Glargine cartridge into the pen correctly and equip the needle. Gently turn the pen upside down for 8-10 times until the insulin in the cartridge becomes uniformly mixed. Adjust the dosage button to get correct dose. After removal of the needle cap and discharge air bubbles in the cartridge, it is ready to be injected. In order to avoid cross contamination, do not let the needle touch anything during the process of preparation. Vial: Firstly, clean your hands. Shake or rotate the vial gently to mix the solution uniformly and check if the insulin has the normal appearance. If using a new Insulin Glargine bottle then flip off the plastic protective cap and wipe the rubber stopper with an alcohol swab. Draw air into your syringe equal to the amount of Insulin Glargine needed. Puncture the needle into the vial and inject the air. Turn the bottle and syringe upside down. Withdraw correct dose of Insulin Glargine into the syringe. Before pulling out the needle, check if there are any bubbles remain in the syringe. If so, put the syringe upright and tap the syringe to discharge the air bubbles. Injection Site: Choose the area where skin is less tight, such as the upper arm, thigh, buttock and abdomen, etc. To avoid tissue damage, choose a site for each injection that is at least 1 cm from the previous injection site. Injection Method: Cleanse the skin with alcohol where the injection is to be made. Put the needle in such a position as to form 45? angle with the skin. Puncture the needle into skin and inject insulin. Then pull the needle out and apply gentle pressure over the injected site for several seconds. Do not rub the injection site.Interaction of Abasaglar Kwikpen 100 IU/mlA number of drugs affect glucose metabolism and may require dose adjustment. The following substances may reduce the Insulin as well as Insulin glargine requirements: Oral anti-diabetic products, angiotensin converting enzyme (ACE) inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, propoxyphene, pentoxifylline, salicylates and sulfonamide antibiotics. The following substances may increase the Insulin as well as Insulin glargine requirements: Thiazides, glucocorticoids, thyroid hormones, beta-sympathomimetics, growth hormone and danazol. Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.ContraindicationsAbasaglar Kwikpen 100 IU/ml is contraindicated in patients with hypersensitivity to insulin glargine or any of its excipients.Side Effects of Abasaglar Kwikpen 100 IU/mlSide effects of Insulin glargine are hypoglycemia, allergic reactions, injection site reaction, lipodystrophy, pruritus, and rash.Pregnancy & LactationPregnancy category C. Insulin glargine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Lactation: It is unknown whether insulin glargine is excreted in human milk. Because many drugs, including human insulin, are excreted in human milk, caution should be exercised when Insulin glargine is administered to a nursing woman. Lactating women may require adjustments in insulin dose & diet.Precautions & WarningsDose adjustment and monitoring: Blood glucose should be monitored in all patients treated with insulin. Insulin regimens should be modified cautiously and only under medical supervision. Administration: Insulin glargine must not be diluted or mixed with any other insulin or solution. It should not be administered subcutaneously via an insulin pump or intravenously because severe hypoglycemia can occur. Renal or hepatic impairment: Reduction in the Insulin glarginedose may require in these cases.Overdose Effects of Abasaglar Kwikpen 100 IU/mlAbasaglar Kwikpen 100 IU/ml overdose may result in hypoglycemia. Mild episodes of hypoglycemia can usually be treated with oral carbohydrates. Severe hypoglycemia may be treated with parenteral glucose or injections of glucagon. Adjustments in drug dosage, meal patterns, or exercise may be needed.Storage ConditionsStore at 2? C to 8? C in a refrigerator. Do not freeze. In case of insulin for recent use need not to be refrigerated, try to keep it in a cool place and keep away from heat and light. The insulin in use can be kept under the room temperature for a month.Use In Special PopulationsUse in Renal/ Hepatic impairment: Reduction in the insulin glargine doses may be required in these cases.
Abasaglar Kwikpen100 IU/ml
Original price was: ₦70,400.00.₦67,584.00Current price is: ₦67,584.00. -
SaleAbdolax 10 mgAbdolax 10 mg is indicated in the following conditions- Constipation of any etiology Relief from prolonged & recurrent constipation Bowel clearance before surgery, childbirth or radiological investigations. Theropeutic ClassOsmotic purgativesPharmacologySodium picosulfate is a stimulant laxative that in conjunction with magnesium citrate, produces a purgative effect on stools. In a multicentre, observational study comprising of patients undergoing colonoscopy, more than 93% of the patients receiving Abdolax 10 mg-containing preparations reported the colon cleansing effect to be effectiveSodium picosulfate is a contact laxative. It inhibits the absorption of water and electrolytes, and increases their secretion into the intestinal lumen. It is hydrolyzed by colonic bacterial enzyme, sulfatase, to form an active metabolite bis-(p-hydroxy-phenyl)-pyridyl-2-methane (BHPM), which acts directly on the colonic mucosa to stimulate colonic peristalsisDosage & Administration of Abdolax 10 mgFor oral administration. The following dosages are recommended to be taken at night to produce evacuation the following morning. It is recommended to start with the lowest dose. The dose may be adjusted up to the maximum recommended dose to produce regular stools. The maximum recommended daily dose should not be exceeded:Adults and children over 10 years of age- Tablet: 5-10 mg per day. Oral Solution: 5-10 ml or one to two teaspoonful per day. Children aged 4-10 years- Tablet: 2.5-5 mg per day. Oral Solution: 2.5-5 ml or Half to one teaspoonful per day. Children under 4 years of age- Oral Solution: 0.25 ml/kg body weight per day. Dosage of Abdolax 10 mgFor oral administration. The following dosages are recommended to be taken at night to produce evacuation the following morning. It is recommended to start with the lowest dose. The dose may be adjusted up to the maximum recommended dose to produce regular stools. The maximum recommended daily dose should not be exceeded:Adults and children over 10 years of age- Tablet: 5-10 mg per day. Oral Solution: 5-10 ml or one to two teaspoonful per day. Children are aged 4-10 years- Tablet: 2.5-5 mg per day. Oral Solution: 2.5-5 ml or Half to one teaspoonful per day. Children under 4 years of age- Oral Solution: 0.25 ml/kg body weight per day. Interaction of Abdolax 10 mgThe concomitant use of diuretics or adreno-corticosteroids may increase the risk of electrolyte imbalance if excessive doses are taken. Concurrent administration of antibiotics may reduce the laxative action of this product.ContraindicationsIleus or intestinal obstruction, severe painful and/or feverish acute abdominal conditions (e.g. appendicitis) potentially associated with nausea and vomiting, acute inflammatory bowel diseases, severe dehydration, known hypersensitivity to Abdolax 10 mg or any other component of the product.Side Effects of Abdolax 10 mgHypersensitivity, dizziness, syncope, vasovagal response, gastrointestinal disorders, diarrhea, abdominal pain and abdominal cramps, nausea, vomiting.Pregnancy & LactationPregnancy: There are no adequate and well-controlled studies in pregnant women. Long experience has shown no evidence of undesirable or damaging effects during pregnancy.Lactation: Clinical data show that neither the active moiety of sodium Picosulfate (BHPM or bis-(p hydroxyphenyl)-pyridyl-2-methane) nor its glucuronides are excreted into the milk of healthy lactating females.Precautions & WarningsProlonged excessive use may lead to fluid and electrolyte imbalance and hypokalemia. Harmful for those suffering from alcoholism. To be taken into account in pregnant or breast-feeding women, children and high-risk groups such as patients with liver disease or epilepsy.Overdose Effects of Abdolax 10 mgLaxatives when taken in chronic overdosage may cause chronic diarrhea, abdominal pain, hypokalemia, secondary hyperaldosteronism, and renal calculi. Renal tubular damage, metabolic alkalosis, and muscle weakness secondary to hypokalemia have also been described in association with chronic laxative abuse.Storage ConditionsKeep below 30?C temperature, away from light & moisture. Keep out of the reach of children.Drug ClassesOsmotic purgativesMode Of ActionAbdolax 10 mg is a triarylmethane group derivative stimulant laxative. After oral administration it is activated by the colonic bacteria and acts locally in the colon. The active form then stimulates the nerve endings of the intestinal wall and results in colonic peristalsis with promotion of accumulation of water and electrolytes in the colonic lumen. This results in stimulation of defecation, reduction of transit time and softening of the stool. Stimulation of the rectum causes increased motility and a feeling of rectal fullness. The rectal effect may help to restore the "call to stool".PregnancyThere are no reports of undesirable or damaging effects during pregnancy or to the foetus attributable to the use of this product. Use of the drug should be avoided during the first trimester. Clinical data show that neither the active moiety of sodium Picosulfate (BHPM or bis-(p hydroxyphenyl)-pyridyl-2-methane) nor its glucuronides are excreted into the milk of healthy lactating females.
Abdolax10 mg
Original price was: ₦5,500.00.₦4,950.00Current price is: ₦4,950.00. -
SaleAbdolax 100 mlAbdolax 100 ml is indicated in the following conditions- Constipation of any etiology Relief from prolonged & recurrent constipation Bowel clearance before surgery, childbirth or radiological investigations. Theropeutic ClassOsmotic purgativesPharmacologySodium picosulfate is a stimulant laxative that in conjunction with magnesium citrate, produces a purgative effect on stools. In a multicentre, observational study comprising of patients undergoing colonoscopy, more than 93% of the patients receiving Abdolax 100 ml-containing preparations reported the colon cleansing effect to be effectiveSodium picosulfate is a contact laxative. It inhibits the absorption of water and electrolytes, and increases their secretion into the intestinal lumen. It is hydrolyzed by colonic bacterial enzyme, sulfatase, to form an active metabolite bis-(p-hydroxy-phenyl)-pyridyl-2-methane (BHPM), which acts directly on the colonic mucosa to stimulate colonic peristalsisDosage & Administration of Abdolax 100 mlFor oral administration. The following dosages are recommended to be taken at night to produce evacuation the following morning. It is recommended to start with the lowest dose. The dose may be adjusted up to the maximum recommended dose to produce regular stools. The maximum recommended daily dose should not be exceeded:Adults and children over 10 years of age- Tablet: 5-10 mg per day. Oral Solution: 5-10 ml or one to two teaspoonful per day. Children aged 4-10 years- Tablet: 2.5-5 mg per day. Oral Solution: 2.5-5 ml or Half to one teaspoonful per day. Children under 4 years of age- Oral Solution: 0.25 ml/kg body weight per day. Dosage of Abdolax 100 mlFor oral administration. The following dosages are recommended to be taken at night to produce evacuation the following morning. It is recommended to start with the lowest dose. The dose may be adjusted up to the maximum recommended dose to produce regular stools. The maximum recommended daily dose should not be exceeded:Adults and children over 10 years of age- Tablet: 5-10 mg per day. Oral Solution: 5-10 ml or one to two teaspoonful per day. Children are aged 4-10 years- Tablet: 2.5-5 mg per day. Oral Solution: 2.5-5 ml or Half to one teaspoonful per day. Children under 4 years of age- Oral Solution: 0.25 ml/kg body weight per day. Interaction of Abdolax 100 mlThe concomitant use of diuretics or adreno-corticosteroids may increase the risk of electrolyte imbalance if excessive doses are taken. Concurrent administration of antibiotics may reduce the laxative action of this product.ContraindicationsIleus or intestinal obstruction, severe painful and/or feverish acute abdominal conditions (e.g. appendicitis) potentially associated with nausea and vomiting, acute inflammatory bowel diseases, severe dehydration, known hypersensitivity to Abdolax 100 ml or any other component of the product.Side Effects of Abdolax 100 mlHypersensitivity, dizziness, syncope, vasovagal response, gastrointestinal disorders, diarrhea, abdominal pain and abdominal cramps, nausea, vomiting.Pregnancy & LactationPregnancy: There are no adequate and well-controlled studies in pregnant women. Long experience has shown no evidence of undesirable or damaging effects during pregnancy.Lactation: Clinical data show that neither the active moiety of sodium Picosulfate (BHPM or bis-(p hydroxyphenyl)-pyridyl-2-methane) nor its glucuronides are excreted into the milk of healthy lactating females.Precautions & WarningsProlonged excessive use may lead to fluid and electrolyte imbalance and hypokalemia. Harmful for those suffering from alcoholism. To be taken into account in pregnant or breast-feeding women, children and high-risk groups such as patients with liver disease or epilepsy.Overdose Effects of Abdolax 100 mlLaxatives when taken in chronic overdosage may cause chronic diarrhea, abdominal pain, hypokalemia, secondary hyperaldosteronism, and renal calculi. Renal tubular damage, metabolic alkalosis, and muscle weakness secondary to hypokalemia have also been described in association with chronic laxative abuse.Storage ConditionsKeep below 30?C temperature, away from light & moisture. Keep out of the reach of children.Drug ClassesOsmotic purgativesMode Of ActionAbdolax 100 ml is a triarylmethane group derivative stimulant laxative. After oral administration it is activated by the colonic bacteria and acts locally in the colon. The active form then stimulates the nerve endings of the intestinal wall and results in colonic peristalsis with promotion of accumulation of water and electrolytes in the colonic lumen. This results in stimulation of defecation, reduction of transit time and softening of the stool. Stimulation of the rectum causes increased motility and a feeling of rectal fullness. The rectal effect may help to restore the "call to stool".PregnancyThere are no reports of undesirable or damaging effects during pregnancy or to the foetus attributable to the use of this product. Use of the drug should be avoided during the first trimester. Clinical data show that neither the active moiety of sodium Picosulfate (BHPM or bis-(p hydroxyphenyl)-pyridyl-2-methane) nor its glucuronides are excreted into the milk of healthy lactating females.
Abdolax100 ml
Original price was: ₦8,250.00.₦7,425.00Current price is: ₦7,425.00. -
SaleAbecab 5 mg+20 mgAbecab 5 mg+20 mg is indicated for the treatment of hypertension, alone or with other antihypertensive agents. This may also be used as initial therapy in patients who are likely to need multiple antihypertensive agents to achieve their blood pressure goals.Theropeutic ClassCombined antihypertensive preparationsPharmacologyAmlodipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle & cardiac muscle. Amlodipine is a peripheral arterial vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral vascular resistance & a reduction in blood pressure.Olmesartan is an angiotensin II receptor blocker that acts on AT1 subtype. By blocking the action of angiotensin II, Olmesartan dilates blood vessels and reduces blood pressure without affecting pulse rate.Dosage & Administration of Abecab 5 mg+20 mgInitial Therapy: The usual starting dose of Abecab 5 mg+20 mg is one tablet (5/20 mg) once daily. Thedosage can be increased after 1 to 2 weeks of therapy to a maximum dose is two tablets (10/40 mg) once daily as needed to control bloodpressure. This may be taken with or without food and may beadministered with other antihypertensive agents.Initial therapy with this combination product is not recommended in patients ?75 years old or with hepatic impairment. Replacement Therapy: Abecab 5 mg+20 mg substituted for its individually titrated components. Whensubstituting for individual components, the dose of one or both of the components can be increased if blood pressure control has not been satisfactory. Add-on Therapy: Abecab 5 mg+20 mg used to provide additional blood pressure lowering forpatients not adequately controlled with Amlodipine (or another dihydropyridinecalcium channel blocker) alone or with Olmesartan Medoxomil (or another angiotensin II receptor blocker) alone.Interaction of Abecab 5 mg+20 mgThe pharmacokinetics of Amlodipine and Olmesartan Medoxomil are not altered when the drugs are co administered. No drug interaction studies have been conducted with Amlodipine and Olmesartan combination tablet and other drugs, although studies have been conducted with the individual Amlodipine and Olmesartan Medoxomil components and no significant drug interactions have been observed.ContraindicationsHypersensitivity to any of the component of this combination product.Side Effects of Abecab 5 mg+20 mgThe reported adverse reactions were generally mild and seldom led to discontinuation of treatment. The most common side effects include edema, dizziness, flushing, palpitation. Other side effects may include vomiting, diarrhoea, rhabdomyolysis, alopecia, pruritus, urticaria etc.Pregnancy & LactationPregnancy: When pregnancy is detected, discontinue this combination product as soon as possible. When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus.Nursing Mothers: Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.Precautions & WarningsFetal/Neonatal Morbidity and Mortality: When pregnancy is detected, this combination should be discontinued as soon as possible.Hypotension in Volume or Salt Depleted Patients: Symptomatic hypotension may occur after initiation of treatment.Vasodilatation: Caution should be exercised when administering the drug, particularly in patients with severe aortic stenosis.Patients with Severe Obstructive Coronary Artery Disease: Patients may develop increased frequency, duration, or severity of angina or acute myocardial infarction on starting calcium channel blocker therapy or at the time of dosage increase.Patients with Congestive Heart Failure: Calcium channel blockers should be used with caution in patients with heart failure.Patients with Impaired Renal Function: Caution should be exercised when administering the drug to patients with renal impairment.Patients with Hepatic Impairment: Caution should be exercised when administering the drug to patients with severe hepatic impairment.Overdose Effects of Abecab 5 mg+20 mgThere is no experience of overdose with Amlodipine & Olmesartan combination. The most likely effects of olmesartan medoxomil overdosage are hypotension and tachycardia; bradycardia could be encountered if parasympathetic (vagal) stimulation occurred.Amlodipine overdosage can be expected to lead to excessive peripheral vasodilatation with marked hypotension and possibly a reflex tachycardia. Marked and potentially prolonged systemic hypotension up to and including shock with fatal outcome has been reported.Storage ConditionsKeep out of the reach of children. Store below 30?C. Keep in the original package in a cool & dry place in order to protect from light and moisture.Use In Special PopulationsThe safety and effectiveness in pediatric patients have not been established.
Abecab5 mg+20 mg
Original price was: ₦6,600.00.₦5,940.00Current price is: ₦5,940.00. -
SaleAbecab 5 mg+40 mgAbecab 5 mg+40 mg is indicated for the treatment of hypertension, alone or with other antihypertensive agents. This may also be used as initial therapy in patients who are likely to need multiple antihypertensive agents to achieve their blood pressure goals.Theropeutic ClassCombined antihypertensive preparationsPharmacologyAmlodipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle & cardiac muscle. Amlodipine is a peripheral arterial vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral vascular resistance & a reduction in blood pressure.Olmesartan is an angiotensin II receptor blocker that acts on AT1 subtype. By blocking the action of angiotensin II, Olmesartan dilates blood vessels and reduces blood pressure without affecting pulse rate.Dosage & Administration of Abecab 5 mg+40 mgInitial Therapy: The usual starting dose of Abecab 5 mg+40 mg is one tablet (5/20 mg) once daily. Thedosage can be increased after 1 to 2 weeks of therapy to a maximum dose is two tablets (10/40 mg) once daily as needed to control bloodpressure. This may be taken with or without food and may beadministered with other antihypertensive agents.Initial therapy with this combination product is not recommended in patients ?75 years old or with hepatic impairment. Replacement Therapy: Abecab 5 mg+40 mg substituted for its individually titrated components. Whensubstituting for individual components, the dose of one or both of the components can be increased if blood pressure control has not been satisfactory. Add-on Therapy: Abecab 5 mg+40 mg used to provide additional blood pressure lowering forpatients not adequately controlled with Amlodipine (or another dihydropyridinecalcium channel blocker) alone or with Olmesartan Medoxomil (or another angiotensin II receptor blocker) alone.Interaction of Abecab 5 mg+40 mgThe pharmacokinetics of Amlodipine and Olmesartan Medoxomil are not altered when the drugs are co administered. No drug interaction studies have been conducted with Amlodipine and Olmesartan combination tablet and other drugs, although studies have been conducted with the individual Amlodipine and Olmesartan Medoxomil components and no significant drug interactions have been observed.ContraindicationsHypersensitivity to any of the component of this combination product.Side Effects of Abecab 5 mg+40 mgThe reported adverse reactions were generally mild and seldom led to discontinuation of treatment. The most common side effects include edema, dizziness, flushing, palpitation. Other side effects may include vomiting, diarrhoea, rhabdomyolysis, alopecia, pruritus, urticaria etc.Pregnancy & LactationPregnancy: When pregnancy is detected, discontinue this combination product as soon as possible. When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus.Nursing Mothers: Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.Precautions & WarningsFetal/Neonatal Morbidity and Mortality: When pregnancy is detected, this combination should be discontinued as soon as possible.Hypotension in Volume or Salt Depleted Patients: Symptomatic hypotension may occur after initiation of treatment.Vasodilatation: Caution should be exercised when administering the drug, particularly in patients with severe aortic stenosis.Patients with Severe Obstructive Coronary Artery Disease: Patients may develop increased frequency, duration, or severity of angina or acute myocardial infarction on starting calcium channel blocker therapy or at the time of dosage increase.Patients with Congestive Heart Failure: Calcium channel blockers should be used with caution in patients with heart failure.Patients with Impaired Renal Function: Caution should be exercised when administering the drug to patients with renal impairment.Patients with Hepatic Impairment: Caution should be exercised when administering the drug to patients with severe hepatic impairment.Overdose Effects of Abecab 5 mg+40 mgThere is no experience of overdose with Amlodipine & Olmesartan combination. The most likely effects of olmesartan medoxomil overdosage are hypotension and tachycardia; bradycardia could be encountered if parasympathetic (vagal) stimulation occurred.Amlodipine overdosage can be expected to lead to excessive peripheral vasodilatation with marked hypotension and possibly a reflex tachycardia. Marked and potentially prolonged systemic hypotension up to and including shock with fatal outcome has been reported.Storage ConditionsKeep out of the reach of children. Store below 30?C. Keep in the original package in a cool & dry place in order to protect from light and moisture.Use In Special PopulationsThe safety and effectiveness in pediatric patients have not been established.
Abecab5 mg+40 mg
Original price was: ₦11,000.00.₦9,900.00Current price is: ₦9,900.00. -
SaleAbetis Plus 20 mg+12.5 mgOlmesartan Medoxomil & Hydrochlorothiazide combination is indicated for the treatment of hypertension.Theropeutic ClassCombined antihypertensive preparationsPharmacologyHydrochlorothiazide inhibits the reabsorption of Na in the distal tubules causing increased excretion of Na and water including K and hydrogen ions.Olmesartan blocks the vasoconstrictor effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in vascular smooth muscle. Its action is therefore independent of the pathways for angiotensin II synthesis.An AT2 receptor is also found in many tissues, but this receptor is not known to be associated with cardiovascular homeostasis. Olmesartan has more than a 12,500-fold greater affinity for the AT1 receptor than for the AT2 receptor.?Blockade of the renin-angiotensin system with ACE inhibitors, which inhibit the biosynthesis of angiotensin II from angiotensin I, is a mechanism of many drugs used to treat hypertension. ACE inhibitors also inhibit the degradation of bradykinin, a reaction also catalyzed by ACE. Because olmesartan medoxomil does not inhibit ACE, it does not affect the response to bradykinin. Whether this difference has clinical relevance is not yet known.Blockade of the angiotensin II receptor inhibits the negative regulatory feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and circulating angiotensin II levels do not overcome the effect of olmesartan on blood pressure.Dosage & Administration of Abetis Plus 20 mg+12.5 mgThe usual recommended starting dose of Olmesartan Medoxomil is 20 mg once daily when used as monotherapy in patients who are not volume-contracted. For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose may be increased to 40 mg. No initial dosage adjustment is recommended for elderly patients, for patients with moderate to marked renal impairment (creatinine clearance30 ml/min. In patients with more severe renal impairment, loop diuretics are preferred to thiazides, so this combination tablet is not recommended.Patients with Hepatic Impairment:?No dosage adjustment is necessary with hepatic impairment.Paediatric population: The safety and efficacy of Olmesartan & Hydrochlorothiazide in children and adolescents below 18 years has not been established. No data are available.Drug ClassesCombined antihypertensive preparationsMode Of ActionAngiotensin-II formed from angiotensin-I in a reaction catalyzed by angiotensin-converting enzyme (ACE), is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system and an important component in the pathophysiology of hypertension. It also stimulates aldosterone secretion by the adrenal cortex. Olmesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin-II by selectively blocking the binding of angiotensin-II to the AT 1 receptor found in many tissues (e.g. vascular smooth muscle, adrenal gland). In-vitro-binding studies indicate that Olmesartan is a reversible & competitive inhibitor of AT 1 receptor. Olmesartan does not inhibit ACE (kinase-I, the enzyme that converts angiotensin-I to angiotensin-II and degrades bradykinin).Hydrochlorothiazide is a thiazide diuretic. Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing the excretion of Sodium and Chloride in approximately equivalent amounts. Indirectly, the diuretic action of Hydrochlorothiazide reduces plasma volume with consequent increases in plasma renin activity, increases Aldosterone secretion & urinary Potassium loss and decreases serum Potassium. The renin-aldosterone link is mediated by angiotensin-II. So, co-administration of an angiotensin-II receptor antagonist tends to reverse the potassium loss associated with these diuretics.PregnancySafety and effectiveness in nursing mother & pregnancy have not been established. The drug should be discontinued during these conditions.Pediatric UsesRenal Impairment Patients: The usual regimens of therapy with this may be followed provided the patient's creatinine clearance is >30 ml/min. In patients with more severe renal impairment, loop diuretics are preferred to thiazides. So, this preparation is not recommended.Hepatic Impairment Patients: No dosage adjustment is necessary with hepatic impairment.Paediatric use: Safety and effectiveness in paediatric patients have not been established.Geriatric use: Clinical studies of Olmesartan and Hydrochlorothiazide combination did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious.
Abetis Plus20 mg+12.5 mg
Original price was: ₦6,050.00.₦5,445.00Current price is: ₦5,445.00. -
SaleAbetis Plus 40 mg+12.5 mgOlmesartan Medoxomil & Hydrochlorothiazide combination is indicated for the treatment of hypertension.Theropeutic ClassCombined antihypertensive preparationsPharmacologyHydrochlorothiazide inhibits the reabsorption of Na in the distal tubules causing increased excretion of Na and water including K and hydrogen ions.Olmesartan blocks the vasoconstrictor effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in vascular smooth muscle. Its action is therefore independent of the pathways for angiotensin II synthesis.An AT2 receptor is also found in many tissues, but this receptor is not known to be associated with cardiovascular homeostasis. Olmesartan has more than a 12,500-fold greater affinity for the AT1 receptor than for the AT2 receptor.?Blockade of the renin-angiotensin system with ACE inhibitors, which inhibit the biosynthesis of angiotensin II from angiotensin I, is a mechanism of many drugs used to treat hypertension. ACE inhibitors also inhibit the degradation of bradykinin, a reaction also catalyzed by ACE. Because olmesartan medoxomil does not inhibit ACE, it does not affect the response to bradykinin. Whether this difference has clinical relevance is not yet known.Blockade of the angiotensin II receptor inhibits the negative regulatory feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and circulating angiotensin II levels do not overcome the effect of olmesartan on blood pressure.Dosage & Administration of Abetis Plus 40 mg+12.5 mgThe usual recommended starting dose of Olmesartan Medoxomil is 20 mg once daily when used as monotherapy in patients who are not volume-contracted. For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose may be increased to 40 mg. No initial dosage adjustment is recommended for elderly patients, for patients with moderate to marked renal impairment (creatinine clearance30 ml/min. In patients with more severe renal impairment, loop diuretics are preferred to thiazides, so this combination tablet is not recommended.Patients with Hepatic Impairment:?No dosage adjustment is necessary with hepatic impairment.Paediatric population: The safety and efficacy of Olmesartan & Hydrochlorothiazide in children and adolescents below 18 years has not been established. No data are available.Drug ClassesCombined antihypertensive preparationsMode Of ActionAngiotensin-II formed from angiotensin-I in a reaction catalyzed by angiotensin-converting enzyme (ACE), is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system and an important component in the pathophysiology of hypertension. It also stimulates aldosterone secretion by the adrenal cortex. Olmesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin-II by selectively blocking the binding of angiotensin-II to the AT 1 receptor found in many tissues (e.g. vascular smooth muscle, adrenal gland). In-vitro-binding studies indicate that Olmesartan is a reversible & competitive inhibitor of AT 1 receptor. Olmesartan does not inhibit ACE (kinase-I, the enzyme that converts angiotensin-I to angiotensin-II and degrades bradykinin).Hydrochlorothiazide is a thiazide diuretic. Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing the excretion of Sodium and Chloride in approximately equivalent amounts. Indirectly, the diuretic action of Hydrochlorothiazide reduces plasma volume with consequent increases in plasma renin activity, increases Aldosterone secretion & urinary Potassium loss and decreases serum Potassium. The renin-aldosterone link is mediated by angiotensin-II. So, co-administration of an angiotensin-II receptor antagonist tends to reverse the potassium loss associated with these diuretics.PregnancySafety and effectiveness in nursing mother & pregnancy have not been established. The drug should be discontinued during these conditions.Pediatric UsesRenal Impairment Patients: The usual regimens of therapy with this may be followed provided the patient's creatinine clearance is >30 ml/min. In patients with more severe renal impairment, loop diuretics are preferred to thiazides. So, this preparation is not recommended.Hepatic Impairment Patients: No dosage adjustment is necessary with hepatic impairment.Paediatric use: Safety and effectiveness in paediatric patients have not been established.Geriatric use: Clinical studies of Olmesartan and Hydrochlorothiazide combination did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious.
Abetis Plus40 mg+12.5 mg
Original price was: ₦9,900.00.₦8,910.00Current price is: ₦8,910.00. -
SaleAbetis 10 mgAbetis 10 mg is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.Theropeutic ClassAngiotensin-ll receptor blockerPharmacologyOlmesartan medoxomil is a potent, orally active, selective angiotensin II receptor (type AT1) antagonist. It is expected to block all actions of angiotensin II mediated by the AT1 receptor, regardless of the source or route of synthesis of angiotensin II. The selective antagonism of the angiotensin II (AT1) receptors results in increases in plasma renin levels and angiotensin I and II concentrations, and some decrease in plasma aldosterone concentrations. Angiotensin II is the primary vasoactive hormone of the renin-angiotensin- aldosterone system (RAAS) and plays a significant role in the pathophysiology of hypertension via the type 1 (AT1) receptor.Dosage & Administration of Abetis 10 mgAdult:?Dosage must be individualized. The usual initial dose is 10 mg once daily. In patients whose blood pressure is not adequately controlled at this dose, the dose may be increased to 20 mg once daily as the optimal dose. For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose of Olmesartan may be increased to 40 mg. Doses above 40 mg do not appear to have greater effect.Pediatric Use: Safety and effectiveness in pediatric patients have not been established.Geriatric Use: Of the total number of hypertensive patients receiving Abetis 10 mg in clinical studies, more than 20% were 65 years of age and over, while more than 5% were 75 years of age and older. No overall differences in effectiveness or safety were observed between elderly patients and younger patients.Dosage of Abetis 10 mgDosage must be individualized. The usual recommended starting dose of Olmesartan is 20 mg once daily when used as monotherapy in patients who are not volume-contracted. For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose of Olmesartan may be increased to 40 mg. Doses above 40 mg do not appear to have a greater effect. Twice-daily dosing offers no advantage over the same total dose given once daily. No initial dosage adjustment is recommended for elderly patients, for patients with moderate to marked renal impairment (creatinine clearance <40 ml/min) or with moderate to marked hepatic dysfunction. For patients with possible depletion of intravascular volume (e.g. patients treated with diuretics, particularly those with impaired renal function), Olmesartan should be initiated under close medical supervision and consideration should be given to use of a lower starting dose. Olmesartan may be administered with or without food.Interaction of Abetis 10 mgWith medicine: No significant drug interactions were reported in which Olmesartan was co-administered.With food & others: Food does not affect the bioavailability of Olmesartan.ContraindicationsOlmesartan is contraindicated in patients who are hypersensitive to any component of this product.Side Effects of Abetis 10 mgCommon: The most common side effects include Back pain, bronchitis, creatine phosphokinase increased, diarrhea, headache, hematuria, hyperglycemia, hypertriglyceridemia, influenza-like symptoms, pharyngitis, rhinitis, and sinusitis.Rare: Chest pain, peripheral edema, arthritis.Pregnancy & LactationPregnancy Categories?C (first trimester) and D (second and third trimesters).Nursing Mothers: It is not known whether Olmesartan is excreted in human milk, but Olmesartan is secreted at low concentration in the milk of lactating rats. Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.Precautions & WarningsAs a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals treated with Abetis 10 mg. In patients whose renal function may depend upon the activity of the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure), treatment with angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotemia and (rarely) with acute renal failure and/or death. Similar results may be anticipated in patients treated with Abetis 10 mg.Overdose Effects of Abetis 10 mgSymptoms: There is no experience of overdose with Olmesartan. The most likely effects of Abetis 10 mg overdosage are hypotension and tachycardia; bradycardia could be encountered if parasympathetic (vagal) stimulation occurred.Treatment: If intake is recent, gastric lavage or induction of emesis may be considered. Clinically significant hypotension due to an overdose of Olmesartan requires the active support of the cardiovascular system, including close monitoring of heart and lung function, the elevation of the extremities, and attention to circulating fluid volume and urine output.Storage ConditionsStore in cool & dry place below 30?C, protect from light & moisture. Keep out of the reach of children.Use In Special PopulationsHepatic Impairment: Dose should not exceed 20 mg daily in moderate impairment.Renal Impairment: Max. 20 mg daily if eGFR 20?60 mL/minute/1.73 m2. Avoid if eGFR less than 20 mL/minute/1.73 m2.Drug ClassesAngiotensin-ll receptor blockerMode Of ActionAngiotensin-II formed from angiotensin-I in a reaction catalyzed by angiotensin-converting enzyme (ACE), is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system and an important component in the pathophysiology of hypertension. It also stimulates aldosterone secretion by the adrenal cortex. Olmesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin-II by selectively blocking the binding of angiotensin-II to the AT 1 receptor found in many tissues (e.g. vascular smooth muscle, adrenal gland). In-vitro-binding studies indicate that Olmesartan is a reversible & competitive inhibitor of AT 1 receptor. Olmesartan does not inhibit ACE (kinase-I, the enzyme that converts angiotensin-I to angiotensin-II and degrades bradykinin).PregnancyPregnancy: When pregnancy is detected, discontinue this product as soon as possible. When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus.Nursing Mothers: It is not known whether Olmesartan is excreted in human milk, but Olmesartan is secreted at low concentration in the milk of lactating rats. Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.Pediatric UsesPaediatric use: Safety and effectiveness in paediatric patients have not been established.
Abetis10 mg
Original price was: ₦3,850.00.₦3,465.00Current price is: ₦3,465.00. -
SaleAbetis 20 mgAbetis 20 mg is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.Theropeutic ClassAngiotensin-ll receptor blockerPharmacologyOlmesartan medoxomil is a potent, orally active, selective angiotensin II receptor (type AT1) antagonist. It is expected to block all actions of angiotensin II mediated by the AT1 receptor, regardless of the source or route of synthesis of angiotensin II. The selective antagonism of the angiotensin II (AT1) receptors results in increases in plasma renin levels and angiotensin I and II concentrations, and some decrease in plasma aldosterone concentrations. Angiotensin II is the primary vasoactive hormone of the renin-angiotensin- aldosterone system (RAAS) and plays a significant role in the pathophysiology of hypertension via the type 1 (AT1) receptor.Dosage & Administration of Abetis 20 mgAdult:?Dosage must be individualized. The usual initial dose is 10 mg once daily. In patients whose blood pressure is not adequately controlled at this dose, the dose may be increased to 20 mg once daily as the optimal dose. For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose of Olmesartan may be increased to 40 mg. Doses above 40 mg do not appear to have greater effect.Pediatric Use: Safety and effectiveness in pediatric patients have not been established.Geriatric Use: Of the total number of hypertensive patients receiving Abetis 20 mg in clinical studies, more than 20% were 65 years of age and over, while more than 5% were 75 years of age and older. No overall differences in effectiveness or safety were observed between elderly patients and younger patients.Dosage of Abetis 20 mgDosage must be individualized. The usual recommended starting dose of Olmesartan is 20 mg once daily when used as monotherapy in patients who are not volume-contracted. For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose of Olmesartan may be increased to 40 mg. Doses above 40 mg do not appear to have a greater effect. Twice-daily dosing offers no advantage over the same total dose given once daily. No initial dosage adjustment is recommended for elderly patients, for patients with moderate to marked renal impairment (creatinine clearance <40 ml/min) or with moderate to marked hepatic dysfunction. For patients with possible depletion of intravascular volume (e.g. patients treated with diuretics, particularly those with impaired renal function), Olmesartan should be initiated under close medical supervision and consideration should be given to use of a lower starting dose. Olmesartan may be administered with or without food.Interaction of Abetis 20 mgWith medicine: No significant drug interactions were reported in which Olmesartan was co-administered.With food & others: Food does not affect the bioavailability of Olmesartan.ContraindicationsOlmesartan is contraindicated in patients who are hypersensitive to any component of this product.Side Effects of Abetis 20 mgCommon: The most common side effects include Back pain, bronchitis, creatine phosphokinase increased, diarrhea, headache, hematuria, hyperglycemia, hypertriglyceridemia, influenza-like symptoms, pharyngitis, rhinitis, and sinusitis.Rare: Chest pain, peripheral edema, arthritis.Pregnancy & LactationPregnancy Categories?C (first trimester) and D (second and third trimesters).Nursing Mothers: It is not known whether Olmesartan is excreted in human milk, but Olmesartan is secreted at low concentration in the milk of lactating rats. Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.Precautions & WarningsAs a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals treated with Abetis 20 mg. In patients whose renal function may depend upon the activity of the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure), treatment with angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotemia and (rarely) with acute renal failure and/or death. Similar results may be anticipated in patients treated with Abetis 20 mg.Overdose Effects of Abetis 20 mgSymptoms: There is no experience of overdose with Olmesartan. The most likely effects of Abetis 20 mg overdosage are hypotension and tachycardia; bradycardia could be encountered if parasympathetic (vagal) stimulation occurred.Treatment: If intake is recent, gastric lavage or induction of emesis may be considered. Clinically significant hypotension due to an overdose of Olmesartan requires the active support of the cardiovascular system, including close monitoring of heart and lung function, the elevation of the extremities, and attention to circulating fluid volume and urine output.Storage ConditionsStore in cool & dry place below 30?C, protect from light & moisture. Keep out of the reach of children.Use In Special PopulationsHepatic Impairment: Dose should not exceed 20 mg daily in moderate impairment.Renal Impairment: Max. 20 mg daily if eGFR 20?60 mL/minute/1.73 m2. Avoid if eGFR less than 20 mL/minute/1.73 m2.Drug ClassesAngiotensin-ll receptor blockerMode Of ActionAngiotensin-II formed from angiotensin-I in a reaction catalyzed by angiotensin-converting enzyme (ACE), is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system and an important component in the pathophysiology of hypertension. It also stimulates aldosterone secretion by the adrenal cortex. Olmesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin-II by selectively blocking the binding of angiotensin-II to the AT 1 receptor found in many tissues (e.g. vascular smooth muscle, adrenal gland). In-vitro-binding studies indicate that Olmesartan is a reversible & competitive inhibitor of AT 1 receptor. Olmesartan does not inhibit ACE (kinase-I, the enzyme that converts angiotensin-I to angiotensin-II and degrades bradykinin).PregnancyPregnancy: When pregnancy is detected, discontinue this product as soon as possible. When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus.Nursing Mothers: It is not known whether Olmesartan is excreted in human milk, but Olmesartan is secreted at low concentration in the milk of lactating rats. Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.Pediatric UsesPaediatric use: Safety and effectiveness in paediatric patients have not been established.
Abetis20 mg
Original price was: ₦6,050.00.₦5,445.00Current price is: ₦5,445.00. -
SaleAbetis 40 mgAbetis 40 mg is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.Theropeutic ClassAngiotensin-ll receptor blockerPharmacologyOlmesartan medoxomil is a potent, orally active, selective angiotensin II receptor (type AT1) antagonist. It is expected to block all actions of angiotensin II mediated by the AT1 receptor, regardless of the source or route of synthesis of angiotensin II. The selective antagonism of the angiotensin II (AT1) receptors results in increases in plasma renin levels and angiotensin I and II concentrations, and some decrease in plasma aldosterone concentrations. Angiotensin II is the primary vasoactive hormone of the renin-angiotensin- aldosterone system (RAAS) and plays a significant role in the pathophysiology of hypertension via the type 1 (AT1) receptor.Dosage & Administration of Abetis 40 mgAdult:?Dosage must be individualized. The usual initial dose is 10 mg once daily. In patients whose blood pressure is not adequately controlled at this dose, the dose may be increased to 20 mg once daily as the optimal dose. For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose of Olmesartan may be increased to 40 mg. Doses above 40 mg do not appear to have greater effect.Pediatric Use: Safety and effectiveness in pediatric patients have not been established.Geriatric Use: Of the total number of hypertensive patients receiving Abetis 40 mg in clinical studies, more than 20% were 65 years of age and over, while more than 5% were 75 years of age and older. No overall differences in effectiveness or safety were observed between elderly patients and younger patients.Dosage of Abetis 40 mgDosage must be individualized. The usual recommended starting dose of Olmesartan is 20 mg once daily when used as monotherapy in patients who are not volume-contracted. For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose of Olmesartan may be increased to 40 mg. Doses above 40 mg do not appear to have a greater effect. Twice-daily dosing offers no advantage over the same total dose given once daily. No initial dosage adjustment is recommended for elderly patients, for patients with moderate to marked renal impairment (creatinine clearance <40 ml/min) or with moderate to marked hepatic dysfunction. For patients with possible depletion of intravascular volume (e.g. patients treated with diuretics, particularly those with impaired renal function), Olmesartan should be initiated under close medical supervision and consideration should be given to use of a lower starting dose. Olmesartan may be administered with or without food.Interaction of Abetis 40 mgWith medicine: No significant drug interactions were reported in which Olmesartan was co-administered.With food & others: Food does not affect the bioavailability of Olmesartan.ContraindicationsOlmesartan is contraindicated in patients who are hypersensitive to any component of this product.Side Effects of Abetis 40 mgCommon: The most common side effects include Back pain, bronchitis, creatine phosphokinase increased, diarrhea, headache, hematuria, hyperglycemia, hypertriglyceridemia, influenza-like symptoms, pharyngitis, rhinitis, and sinusitis.Rare: Chest pain, peripheral edema, arthritis.Pregnancy & LactationPregnancy Categories?C (first trimester) and D (second and third trimesters).Nursing Mothers: It is not known whether Olmesartan is excreted in human milk, but Olmesartan is secreted at low concentration in the milk of lactating rats. Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.Precautions & WarningsAs a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals treated with Abetis 40 mg. In patients whose renal function may depend upon the activity of the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure), treatment with angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotemia and (rarely) with acute renal failure and/or death. Similar results may be anticipated in patients treated with Abetis 40 mg.Overdose Effects of Abetis 40 mgSymptoms: There is no experience of overdose with Olmesartan. The most likely effects of Abetis 40 mg overdosage are hypotension and tachycardia; bradycardia could be encountered if parasympathetic (vagal) stimulation occurred.Treatment: If intake is recent, gastric lavage or induction of emesis may be considered. Clinically significant hypotension due to an overdose of Olmesartan requires the active support of the cardiovascular system, including close monitoring of heart and lung function, the elevation of the extremities, and attention to circulating fluid volume and urine output.Storage ConditionsStore in cool & dry place below 30?C, protect from light & moisture. Keep out of the reach of children.Use In Special PopulationsHepatic Impairment: Dose should not exceed 20 mg daily in moderate impairment.Renal Impairment: Max. 20 mg daily if eGFR 20?60 mL/minute/1.73 m2. Avoid if eGFR less than 20 mL/minute/1.73 m2.Drug ClassesAngiotensin-ll receptor blockerMode Of ActionAngiotensin-II formed from angiotensin-I in a reaction catalyzed by angiotensin-converting enzyme (ACE), is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system and an important component in the pathophysiology of hypertension. It also stimulates aldosterone secretion by the adrenal cortex. Olmesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin-II by selectively blocking the binding of angiotensin-II to the AT 1 receptor found in many tissues (e.g. vascular smooth muscle, adrenal gland). In-vitro-binding studies indicate that Olmesartan is a reversible & competitive inhibitor of AT 1 receptor. Olmesartan does not inhibit ACE (kinase-I, the enzyme that converts angiotensin-I to angiotensin-II and degrades bradykinin).PregnancyPregnancy: When pregnancy is detected, discontinue this product as soon as possible. When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus.Nursing Mothers: It is not known whether Olmesartan is excreted in human milk, but Olmesartan is secreted at low concentration in the milk of lactating rats. Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.Pediatric UsesPaediatric use: Safety and effectiveness in paediatric patients have not been established.
Abetis40 mg
Original price was: ₦990.00.₦891.00Current price is: ₦891.00.